Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 173

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer

Open access
Yu, Meifang, Nguyen, Nicholas D., Huang, Yanqing, Lin, Daniel, Fujimoto, Tara N., Molkentine, Jessica M., Deorukhkar, Amit, Kang, Ya’an, San Lucas, F. Anthony, Fernandes, Conrad J., Koay, Eugene J., Gupta, Sonal, Ying, Haoqiang, Koong, Albert C., Herman, Joseph M., Fleming, Jason B., Maitra, Anirban, Taniguchi, Cullen M.·2019·JCI Insight

Abstract

Pancreatic ductal adenocarcinoma (PDAC) requires mitochondrial oxidative phosphorylation (OXPHOS) to fuel its growth, however, broadly inhibiting this pathway might also disrupt essential mitochondrial functions in normal tissues. PDAC cells exhibit abnormally fragmented mitochondria that are essential to its oncogenicity, but it was unclear if this mitochondrial feature was a valid therapeutic target. Here, we present evidence that normalizing the fragmented mitochondria of pancreatic cancer via the process of mitochondrial fusion reduces OXPHOS, which correlates with suppressed tumor growth and improved survival in preclinical models. Mitochondrial fusion was achieved by genetic or pharmacologic inhibition of dynamin related protein-1 (Drp1) or through overexpression of mitofusin-2 (Mfn2). Notably, we found that oral leflunomide, an FDA-approved arthritis drug, promoted a two-fold increase in Mfn2 expression in tumors and was repurposed as a chemotherapeutic agent, improving the median survival of mice with spontaneous tumors by 50% compared to vehicle. We found that the chief tumor suppressive mechanism of mitochondrial fusion was enhanced mitophagy, which proportionally reduced mitochondrial mass and ATP production. These data suggest that mitochondrial fusion is a specific and druggable regulator of pancreatic cancer growth that could be rapidly translated to the clinic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci.insight.126915

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 173

Metadata

Authors
Yu, M., Nguyen, N. D., Huang, Y., Lin, D., Fujimoto, T. N., Molkentine, J. M., Deorukhkar, A., Kang, Y., San Lucas, F. A., Fernandes, C. J., Koay, E. J., Gupta, S., Ying, H., Koong, A. C., Herman, J. M., Fleming, J. B., Maitra, A., & Taniguchi, C. M.
Venue
JCI Insight
Published
2019-08-22
Volume
4
Issue
16
ISSN
2379-3708 (ISSN-L)
OpenAlex
W2963642174
Cited by
173
References
17
FWCI
5.37
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. https://app.cochat.ai/papers/10.1172/jci.insight.126915
The paper
Yu, M., Nguyen, N. D., Huang, Y., Lin, D., Fujimoto, T. N., Molkentine, J. M., Deorukhkar, A., Kang, Y., San Lucas, F. A., Fernandes, C. J., Koay, E. J., Gupta, S., Ying, H., Koong, A. C., Herman, J. M., Fleming, J. B., Maitra, A., & Taniguchi, C. M. (2019). Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. JCI Insight. https://doi.org/10.1172/jci.insight.126915

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.